TABLE 3.
Studies that assessed risk of cancer according to the TCN2 rs1801198 (c.776G>C) polymorphism1
| Cases, n |
Controls, n |
|||||||
| Reference | STREGA score | Type of cancer | Country (ethnicity) | Study design | Total | CC/CG/GG | Total | CC/CG/GG |
| Hazra et al., 2007 (53) | 14 of 19 | Colorectal adenoma | United States (Caucasians) | Case-control | 522 | 150/273/99 | 522 | 182/248/92 |
| Koushik et al., 2006 (54) | 14 of 19 | Colorectal cancer | United States (Caucasians) | Case-control | 349 | 119/168/62 | 796 | 249/392/155 |
| Semmler et al., 2006 (55) | 12 of 19 | Glioblastoma multiforme | Germany (Caucasians) | Case-control | 328 | 92/151/85 | 400 | 110/180/110 |
| Kurzwelly et al., 2010 (56) | 11 of 19 | PCNSL | Germany (Caucasians) | Case-control | 185 | 61/76/48 | 212 | 57/100/55 |
| Pawlik et al., 2012 (57) | 12 of 19 | Ovarian cancer | Poland (Caucasians) | Case-control | 134 | 50/58/26 | 160 | 48/77/35 |
1
PCNSL, primary central nervous system lymphoma; STREGA, Strengthening the Reporting of Genetic Association Studies; TCN2, transcobalamin 2.